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ABSTRACT
Poor lung cancer survival can largely be contributed to the metastatic cells that invade
and spread throughout the body. The tumor microenvironment (TME) is composed of multiple
cell types, as well as non-cellular components. The TME plays a critical role in the development
of metastatic cancers by providing migratory cues that change the growing tumor’s properties.
The Extracellular Matrix (ECM), a main component of the TME, has been shown to change
composition during tumor progression, allowing cancer cells to invade tissue and survive away
from the primary cancer site. Although the ECM is well-known to influence the fate of tumor
progression, little is known about the molecular mechanisms that are affected by the cancer cellECM interactions. It is imperative that these mechanisms are understood in order to properly
understand and prevent lung cancer dissemination. However, common in vitro studies do not
incorporate these interactions into everyday cell culture assays. In our lab, we have adopted a
model that examines decellularized human fibroblast-derived ECM as a 3D substrate for growth
of lung adenocarcinoma cell lines. It is hypothesized that the interactions between lung cancer
cell lines and fibroblast-derived ECM will alter phenotypes important for lung cancer
progression. Here, we have characterized the effect of various fibroblast-derived matrices on the
properties of various lung cancer adenocarcinoma cell lines. Such altered processes include
morphology, growth, and migration. This work highlights the significance of the cell-ECM
interaction and its requirement for incorporation into in vitro experiments. Implementation of a
fibroblast-derived ECM as an in vitro technique will provide researchers with an important factor
to manipulate to better recreate and study the TME.
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I. Introduction
The five-year survival rate for stage 3 lung cancer patients is only around 15% (American
Cancer Society, 2015). This poor survival rate is largely contributed to the metastatic form of the
disease, which allows the cancer to become a systemic burden, by infiltrating vital organs. 40%50% of patients with Non-small-cell lung cancers (NSCLC), which is the classification for nearly
80% of all lung cancers, have metastatic lung cancer at diagnosis (Ihde et al., 1992). Although
survival rates improve with early detection, there is a great need for efficacious therapies that
treat the metastatic form of lung cancer. There are many FDA approved therapies that are
successful

for

lung

cancer

patients

(eg.

surgical

resection,

local

radiation,

and

chemotherapeutics), but few therapies exist that are effective at specifically targeting cancer
cells, while leaving healthy cells untouched, and even fewer that are effective against the
metastatic cancers. This failure to produce effective therapies is partly due to false discoveries
that are attributed to lack of appropriate models that accurately recapitulate the in vivo
mechanisms that drive lung cancer and its progression to metastasis (Hoelder et al., 2012). For
instance, many cancer therapies are developed from chemicals that illicit a cancer specific
cytotoxic response during in vitro cell culture environments, but these cell culture environments
do not offer the full biological repertoire that is present in the human disease. This means that
researchers are limited in the accuracy of their conclusions thus leading them down an incorrect
path that may ultimately result in failure in the clinical setting. Although cell culture experiments
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are a simple first-line test for new therapies, an improved in vitro model could filter out
inefficacious treatments before large financial and temporal investments are made.
It is now a fully accepted paradigm that neoplasms are a dynamic environment that host
multiple cell types that influences the behavior and outcome of the cancer (Wood et al., 2014).
Many studies are being done to determine the exact role the tumor microenvironment (TME)
constituents, which include cancer cells, immune cells, fibroblasts, vasculature, and the
extracellular matrix (ECM) (Schwendener et al., 2014) (Figure 1). The immune cells have been
heavily studied for their role in carcinogenesis because they can support tumor growth and
influence angiogenesis by secreting the necessary growth factors, which include VEGF and IL-8
(Wood et al., 2014). Cancer-associated fibroblasts (CAFs), which are fibroblasts that reside
within the tumor, but differ from normal resident fibroblasts, have also been shown to be protumorigenic by providing growth factors TGF-β, PDGF, and FGF, as well as cytokines such as
IL-8, CXCL14, and IL-6 (Cirri et al., 2011). Many novel therapies have been produced that
target the TME. For instance, Bevacizumab is a monoclonal antibody that inhibits lung cancer
angiogenesis by targeting VEGF (Das et al., 2012). It is clear that the best way to treat the patient
is to treat the entire TME.
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Figure 1- The Tumor Microenvironment
The ECM, an essential constituent of the TME, is a meshwork of protein fibers and
glycosanimoglycans (GAGs) that not only provides mechanical support, but also offers growth
and migration cues through growth factors, adhesion interactions, and mechano-transduction
(Oskarsson et al., 2013). The ECM is generally secreted and organized by fibroblasts, but other
cells can contribute to ECM production, such as endothelial and epithelial cells (Lu et al., 2012).
Lately, the ECM has been heavily researched for its role in the progression of lung and breast
carcinomas (Lu et al., 2012; Oskarsson et al., 2013; Yang et al., 2011). The balance of ECM
deposition and ECM degradation can potentiate diseases such as fibrosis and cancer (Cox et al.,
2011). Increased production of the high elastic modulus collagen and decreased low elastic
modulus elastin expression can stiffen local tissue, therefore altering mechano-transduction
pathways (Butcher et al., 2009). Matrix metalloproteases (MMPs) are matrix-degrading enzymes
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that can degrade the ECM and alter its elasticity, which can provide cells with important
biomechanical stimulation to direct invasion into surrounding tissue and blood vessels, leading to
metastasis (Hadler-Olsen et al., 2013). Alternately, ECM can be stiffened by increased matrix
production and deposition of collagen via Lysyl Oxidase (LOX) signaling (Gao et al., 2010). For
instance, ECM accumulation by increased Collagen deposition has been documented in many
tumor cell types, including glioma, breast, and lung cancers (Huijbers et al., et al; Caccavari et
al., 2010). This abnormal ECM function can cause changes in the mechano-transduction
pathways that regulate growth and migration pathways. Tension-induced signaling has been
shown to affect Mitogen-Activated Protein Kinase (MAPK) signaling pathways by p44/42
activation in fetal lung epithelial cell lines (Copland et al., 2007). MAPK signaling is highly
affected in cancer that activates many downstream applications. Similarly, focal adhesions are
the point of cell-ECM matrix interaction and are comprised of integrins that cluster together and
bind the ECM, thus triggering downstream pathways mediated through Focal Adhesion Kinase
(FAK) (Caccavari et al., 2010). These downstream signaling pathways have the ability to
modulate MMP and tissue inhibitors of metalloproteases (TIMP) that can adjust ECM synthesis
and degradation (Caccavari et al., 2010). It is now evident that there exists a complex feedback
mechanism between cancer cells and ECM that influences the fate of the tumor (Blaauboer et al.,
2014). Interference of the cancer-promoting ECM-cell interactions could immobilize cancer
cells and inhibit the deadly metastatic form of lung cancer, thus improving patient survival rates.
Therefore, more basic research is needed to understand how lung ECM affects lung cancer cells,
and vice versa.
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To improve the reconstruction of the in vivo TME in vitro, cancer researchers are
growing cancer cells in three-dimensions, rather than the commonly used 2D- tissue culturedtreated dishes. Matrigel™, a basement membrane extract (BME) harvested from EHS mouse
sarcoma cells, is a common semi-solid medium used to recapitulate the in vivo environment that
affects cell morphology, proliferation, migration, and drug response ( Benton et al., 2011). There
also exists synthetic cell scaffolds such as hyaluronic acid, gelatin, or polyethylene, but these
synthetic gels and substrates lack the rich diversity of the stroma-associated ECM that is present
in vivo. Also, both Matrigel™ and synthetic matrices lack the native fibrillar architecture that
may be required for the complex mechanisms of the cancer cell-ECM interaction. Also, BME,
like Matrigel™, are not tissue specific, which could make interpreting effects difficult because
different ECM protein compositions could have different effects on the biology of the tissuespecific cancer cell. Although suspending cancer cells in 3D protein gels better mimic the native
tumor, it does not accurately recapitulate many tumors of the epithelium, including lung
adenocarcinoma. Therefore, it is necessary to implement a better tissue-culture technique that
incorporates signals from extracellular matrix proteins and structural properties.
Fibroblast-derived ECM could be a simple, cost-effective cell culture technique that
recapitulates the ECM-lung cancer cell interactions that have been shown to play a vital role in
the progression of cancer. Fibroblasts are the principal contributors to ECM synthesis in most
types of tissue, including the lung epithelium. Therefore, an ECM synthesized by fibroblast that
retains its structural architecture will more accurately represent the native tumor environment.
Edna Cukierman et al have published numerous articles describing techniques to harvest mouse
fibroblast-derived matrices, and even characterized how these matrices affect the morphology,
5

growth, and drug response of numerous epithelial tumors cell lines, but no lung adenocarcinoma
cells with human lung matrix were tested (Serebriiskii et al., 2008). Further, the same group
demonstrated that overexpression of Fibroblast-activated Protein (FAP) in 3T3 cells induced
matrix fiber alignment, which increased the growth invasiveness of pancreatic cancer cells (Lee
et al., 2011). Still, little is known about how human lung fibroblast-derived matrices alter the
morphology, growth, invasiveness, and biochemical properties of lung cancer cell lines.
In this work, we sought to better understand the effect of tissue-specific, human lung
fibroblast-derived matrices on two lung adenocarcinoma cell lines, A549, H358, and HPL1Ds in
ways previously untested with fibroblast-derived ECM. Techniques such as cell growth assays,
drug response, microscopy, western blot, RNA analysis, and migration studies were used to
characterize human fibroblast-derived ECM and how they affect lung cancer cell lines. The
Objective of this Masters of Engineering project is to characterize the effect of human fibroblastderived extracellular matrix on lung cancer cell phenotypes. Also, it is a long-term goal of the
student to understand how modulation of the fibroblast-derived extracellular matrix alters human
lung cancers.
II. METHODS
A. Cell Culture
Three Human fibroblast cell lines were used in this study, IMR-90, WI-38, and HDF, were
all purchased from ATCC. IMR-90 Cells are human lung fibroblasts harvested from a female of
16-week gestation. WI-38 cells are also lung fibroblasts harvested from a 12-week old fetus.
HDFs are human dermal fibroblast procured from the Patricia Soucy Laboratory. IMR90 and
6

HDF cells were both cultured in RPMI 1640 (Hyclone SH30027.01) supplemented with 10%
FBS (Hyclone SH30070.03), 1% penicillin-streptomycin (Hyclone SV30030), and 1% Lglutamine (Hyclone SH30034.01). WI-38 cells were cultured in MEM media (Gibco 10370-021)
supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% L-Glutamine.
Three-epithelial cell lines, A549, H358, and HPL1D, purchased from ATCC, were used to
seed onto Fibroblast-derived matrix. A549 and H358 cells are both lung adenocarcinoma cells
harvested in 1972, and 1981, respectively. HPL1D cells are normal peripheral lung epithelial
cells and were used to compare the cancerous phenotype of A549 and H358 cell lines to normal,
steady-state lung epithelial cells. However, HPL1D cells have been shown to form soft-agar
colonies in our lab, suggesting they are transformed. All epithelial cells were cultured in RPMI
1640 supplemented with 10% FBS, 1% Glutamine, and 1% penicillin-streptomycin.
B. Extracellular Matrix Production and Decellularization
ECM production and harvesting protocols were adapted from Cukierman et al and Soucy et
al (Soucy et al., 2009). Fibroblasts are seeded at confluence, and cultured for 8 days while
changing the media every two days. HDF cells are a little larger that the lung fibroblast cell lines
so they are seeded at a lower density than WI-38 and IMR-90 cells. For example, in a 6 well
dish, 300,000 IMR90 or WI-38 cells are seeded, but for the same size dish, 270,000 HDF cells
were seeded. After 8 days of culture, cells are washed once with PBS (Hyclone SH30028.02),
and then incubated at room temperature for 2 minutes in PBS with 50 mM concentration of
ammonium Hydroxide (NH4OH) (Fischer-A669-500) with .05% Triton X-100 (Sigma T8787)
solution. Ammonium hydroxide is used to destroy the fibroblasts by creating a hypotonic
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solution that lyses the cells. Triton X-100 is a detergent that also aides in cell lysis while leaving
the produced matrix undisturbed. Cells are constantly observed under the microscope at 10X to
confirm proper removal of all fibroblast debris. After decellularization, the matrices are washed
3 times with PBS. To prevent unwanted fibroblast DNA, which could affect downstream
applications, matrices are incubated at for one hour at 37°C in a 20U/mL DNAse 1(Thermo
Scientific EN0525) concentration in sterile H2O (CellGro 25-055-CV). After DNAse 1
treatment, matrices are washed 3 times with PBS and either stored at 4°C, or used immediately
(Figure 2).

Figure 2- Schematic of Fibroblast-derived ECM protocol
C. Microscopy and Fluorescent Microscopy
For light microscopy, a Zeiss AX10 inverted microscope was used at 10X and 40X. For
Immunofluorescence, a Nikon A1R camera mounted on a Zeiss Confocal microscope was used.
For immunofluorescence, Matrices and/or cells were fixed with 4% formaldehyde in PBS for 20
minutes at room temperature then washed 3 times with PBS for 5 minutes each. For ECM
staining, a succinimidyl ester (NHS ester) conjugated to an Alexa Fluor 488 dye was incubated at
a concentration of 10 µg/mL for 30 minutes at 37°C, then washed 3 times with PBS for 5
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minutes. The NHS ester binds to any proteins, thus staining the entire extracellular matrix. To
ensure no leftover fibroblast DNA is present, DAPI was also added at a concentration of 1:1000
in PBS for 10 minutes at room temperature. To image the cytoskeleton of epithelial cells,
Phalloidin was added at a concentration of 1:1000, while incubating with DAPI for 10 minutes at
room temperature. After staining, the cells were imaged. The ECM stain fluoresces at 488 nm,
while Phalloidin and DAPI fluoresce at 600 nm and 358 nm, respectfully.

D. SDS PAGE and Western Blot
Cells were lysed in CHAPS buffer (1% CHAPS in 150 nM NACL, 50 mM TRIS pH 7.5, 50
mM EDTA) containing protease and phosphatase inhibitors for 20 minutes on ice. Lysates were
centrifuged at 15,000 X G for 8 minutes at 4°C to pellet the insoluble material, which includes
the extracellular matrix proteins. Protein concentration was then quantified using a bicinchoninic
acid (BCA) assay (Thermo Scientific #23228, #1859078). Briefly, the BCA assay is a 2-step
reaction where peptide bonds reduce the copper sulfate in reagent-A, next the reduced copper is
chelated by the bicinchonic acid from reagent-B, forming a purple color, which can be measured
at 562 nm by absorption on a spectrophotometer. The amount of reduced copper ions and
therefore the absorbance at 562 nm is directly proportional to the amount of protein in the
sample. 30 µg of total protein was loaded on a 4-12% bis-tris polyacrylamide gel (Novex). 150
volts was applied across the gel for 60 minutes at room temperature while the gel was submerged
in 1X running buffer (Novex NP0002) in water. After protein migration, gels were either stained
with colloidal blue (Invitrogen LC6025) for 4 hours to stain nonspecific proteins, or
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immunoblotting was performed. For immunoblotting, protein was transferred to a PVDF
membrane by applying a voltage of 70 V for 60 minutes in 1X transfer buffer (Novex NP0006)
diluted with water and methanol. After protein transfer, membranes were washed for 15 minutes
in 5% milk in a mixture of Tris-buffered saline and Tween 20 (TBS-T) to block non-specific
binding by the antibody. Primary antibodies specific to human GAPDH, AKT, phosphorylated
AKT, p38, phosphorylated p38, p44/42, phosphorylated p44/42, E-cadherin, Vimentin, mTOR,
phosphorylated mTOR, and CDC42 (Cell Signaling™) were added at a concentration of 1:10000
in 5% milk and incubated with the membranes overnight at 4°C. After primary antibody
incubation, membranes were washed 3 times in 5% milk for 5 minutes. Secondary antibody,
conjugated to HRP, specific to target the primary rabbit antibody, was incubated with the
membranes in 1.25% milk for 30 minutes at room temperature then washed 2 times for 5 minutes
in 1.25% milk. Membranes were then incubated for 20 minutes in TBS-T before adding HRP
substrate (Thermo Scientific #34095) for detection by luminescence captured on a photographic
film. The amount of luminescence produced by the HRP enzymatic reaction is proportional to
the amount of protein tagged by the antibody.
E. Cell Growth
To determine the effect of cell-derived matrices on cell growth and proliferation, two assays
were employed. To determine cell number, 30,000 cells were plated in a 12 well dish with a
fibronectin coat, or fibroblast-derived ECM. Every 24 hours for 4 days, cells were washed in
PBS, trypsinized in Trypsin (Hyclone SH30042.01) for 3 minutes at 37°C, centrifuged at 1200
RPM for 3 minutes and suspended in 1 mL media for counting with Trypan Blue™ (Invitrogen
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T10282) in a Countess automated cell counter m (Invitrogen). Trypan blue is a dye used to stain
dead cells, which does not stain live cells.
For proliferation, 2,000 cells were seeded into a 96 well-plate, and Alamar Blue™
(Invitrogen 612130) was added each day for 4 days to determine proliferation. Plates were
incubated at 37°C until a color changed was observed, then read on a spectrophotometer using an
excitation of 560 nm and emission of 590 nm. Briefly, Alamar Blue™ is resazurin and enters the
cell and gets reduced by cells with an active metabolism. The reaction converts a blue resazurin
to a purple resorufin, a fluorescent molecule. Raw fluorescent data were averaged, with the blank
reading subtracted, and then normalized to Fibronectin.
F. Trans-well Migration Assay
To determine if fibroblast-derived matrices affected how epithelial cells migrate, trans-well
chamber (Fischer 353097) assays were used. Briefly, ECM was produced on the bottom side of a
trans-well chamber (Figure 3A-C) and A549 cells were cultured on the top side (Figure 3D).
After 24 and 48 hours, non-migrating cells were scraped off the membrane. Migrating cells were
then fixed in 4% paraformaldehyde and stain with hemotoxylin and eosin (Protocol 122-911).
Membranes were then mounted on a glass slide and migrated cells were counted using ImageJ
software analysis. N=4.
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Figure 3- Depiction of Trans-well Assay. (3A) Seed 50,000 fibroblasts on membrane and
allow to adhere. (3B) Properly insert chamber 28 hours seeding. (3C) After 8 days,
decellularize. (3D) seed 15,000 A549 Cells in upper portion of chamber. (3E) allow cells
to migrate for 24 hours.

G. Microarray
RNA was harvested using E.Z.N.A Total RNA Kit (Omega) and analyzed on a nanodrop for
quality control. RNA must have a 260/280 absorbance ratio between 1.8 and 1.9, and a 260/230
absorbance ratio between 1.9 and 2.2 to ensure minimal protein contamination then treated with
DNAse to remove DNA contamination. RNA samples were then converted to cDNA, labeled,
and hybridized on an Affymetrix PrimeView Human Array Chip with the aid of the Genomics
Core Facility and the assistance of the student. Raw intensity scores were imported into Partek
Genomics Suite 6.6 (6.13.0731) and normalized on a gene level using the standard RMA
algorithm for normalization and background correction. A 2-way ANOVA was set up and a stepup FDR corrected P-value was included for every P-value calculated. Only significant gene
changes with a P-value of <.05 and a fold change greater than 1.5 were uploaded into
MetaCore™ for pathway and gene otology analysis.
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H. Real Time PCR
New biological replicates were used to generate RNA as previously described for the
microarray. Complementary DNA was generated using the RNA to cDNA kit Applied
Biosystems). This kit uses thymidine-rich primers that bind to the poly-A tail of mRNA and
allow a polymerase to synthesize the complete complimentary strand. Oligonucleotide
sequences are as follows:
Table I
List of Primer sequences for Quantitative PCR
Antisense

Gene

Sense

LGALS

GGTCAACCCTGAAGATCACAG

GTCCAATGAGTTGCAGACAATG

PSAT1

AAGGTGTGCTGACTATGTGG

TTGAGGTTCCAGGTGCTTG

ASNS

AGGAGAGTGAGAGGCTTCTG

GGTGGCAGAGACAAGTAATAGG

BCAT1

AATCCCAAGTATGTAAGAGCCTG

AAGAGATGAGCCGTAATTCCC

IL-8

ATACTCCAAACCTTTCCACCC

TCTGCACCCAGTTTTCCTTG

STAT4

CCTGAAAACCCTCTGAAGTACC

ACCTTTGTCACCCCTTTCTG

C3

AACTACATCACAGAGCTGCG

AAGTCCTCAACGTTCCACAG

C1S

TTTGTAGATGTCCCTTGTAGCC

AATCTCCCCAATCAGTGCAG

MMP7

TTCCAAAGTGGTCACCTACAG

AGTTCCCCATACAACTTTCCTG

RND1

ATGTAAGCTCGTTCTGGTCG

CTCTGTTCCTCTGTCTCCAAAC

GAPDH

TGCACCACCAACTGCTTAGC

GGCATGGACTGTGGTCATGAG
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Primers were designed to be between 18-22 base pairs long, have a 40%-60% GC content,
and amplify a product between 60-120 base-pairs. Primer specificity was validated to only
amplify one product between at 60°C. Reaction efficiency was also validated to ensure that
fluorescence intensity doubled each cycle using a serial dilution of a known cDNA template.
Reactions were shown to be efficient between 10 ng and 50 ng concentrations of DNA. To
qualify, efficiency must be within 85% and 105% with an R2 value greater than .98. This quality
control confirms that no matter the differences in original starting material between the wells,
comparison of threshold values are valid because the samples are within the linear range. To
calculate relative fold change compared to a fibronectin-coated dish, the 2 ΔΔCT method.
Equations shown below:
𝛥𝛥𝐶𝑇 = (𝛥𝐶𝑇(𝐸𝐶𝑀) − 𝛥𝐶𝑇(𝐹𝑁))
𝛥𝐶𝑇 = 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐶T (𝑇𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒) − 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐶𝑇 (𝐺𝐴𝑃𝐷𝐻).
CT is the PCR cycle number where the fluorescent threshold value is reached. All PCR
reactions were analyzed on a biorad CX96.
I. TIME-LAPSE MICROSCOPY
150,000 A549 cells were seeded onto either ECM-coated or Fibronectin-coated 35mm dishes
with a coverslip insert for microscopy. 24 hours after cell seeding, dishes were inserted into a
live-cell chamber for 24 hours and pictures were taken at 3 different fields every 10 minutes,
until 24 hours have past. Cell migration was calculated by tracking 4-8 cells per field throughout
the time lapse. Cell tracking was achieved by the MtrackerJ plugin, available for ImageJ
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(Meijering et al., 2012). Average point by point velocity for all lines were calculated within
MtrackerJ and reported with SEM. Directionality, a measure to determine linearity of migration,
was calculated by D/d (Figure 13B).
J. Cell Circularity
After confocal microscopy with Phallodin and DAPI, images with scale bars were
imported in ImageJ and converted from RGB to 32-bit and a threshold was set to create
maximum contrast between cell borders and empty space. Built-in functions of ImageJ allowed
for easy image segmentation for area and perimeter analysis. Circularity is a value between 0-1
with 1 being a perfect circle (Pasqualato et al., 2013).

𝐶𝑖𝑟𝑐𝑢𝑙𝑎𝑟𝑖𝑡𝑦 = 4𝜋 × (𝐴𝑟𝑒𝑎 ÷ 𝑃𝑒𝑟𝑖𝑚𝑒𝑡𝑒𝑟 2 )

K. Subcutaneous Tumor Formation
5x106 cells in 500 µL were mixed with either 500 µL PBS or 500 µL of PBS with 615 µg
scraped WI38 derived ECM. 100 µL was then injected in the subcutaneous tissue of NRG mice.
Each mouse received two injections: 100 µL of A549 cells with ECM on the left flank and 100
µL of A549 with PBS on the right flank. Tumors were then allowed to form and after 60 days,
mice were euthanized by CO2 and tumors were excised and fixed in 10% buffered
formaldehyde. Fixed tissues were sent to HistoServe™ for paraffin embedding, sectioning, and
staining. Tumor volume is measured by:
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1
(𝐿𝑒𝑛𝑡ℎ 𝑥 𝑊𝑖𝑑𝑡ℎ)2
2

𝑇𝑢𝑚𝑜𝑟 𝑉𝑜𝑙𝑢𝑚𝑒 =

Where length is the greatest longitudinal direction and width is the greatest transverse direction
(Jensen et al., 2008).
L. Dose Response of Chemotheraputics
3,000 A549, H358, and HPL1D cells were seeded in on a 96 well-plate. After 24 hours,
Cisplatin and Gemcitabine were added into the media and then incubated for 48 hours before
measuring cell growth by Alamar Blue™. N=3.
M. Statistical Analysis
A two-way ANOVA with a Tukey’s Test for multiple comparisons were used to
determine statistical significance. For in vivo data, a unpaired t-test was performed. *, Pvalue<.05

III. Results and Discussion
A. Fibroblasts and Their Derived Extracellular Matrix
In order to derive accurate conclusions, multiple fibroblast cell lines were procured to
produce a variety of ECM from multiple tissue types. Two human fetal lung fibroblasts cell
lines, WI38 and IMR-90, and one human dermal fibroblast cell line, HDF, were used. All
fibroblast cell lines exhibited the same spindle-shaped morphological features (Figure 4Ai).
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Interestingly, all three fibroblast cell lines aligned themselves in a linear pattern, and produced a
similar ECM, which also appeared highly linearized, suggesting there is dynamic remodeling
after cell seeding (Figure 4Aii and 4Aiii). This linearized ECM could be important for
maximizing physiologic relevance to the human disease in vitro, which is not available with
solubilized ECM, such as Matrigel™. The resultant fibroblast-derived ECM was solubilized in
5M Guanidine-HCL and protein content was measured using a BCA assay (figure 4C). All
fibroblast-derived matrix produced similar amounts of ECM per cm2, except HDF produces
slightly more (P=045). WI38 ECM averaged 32.06 µg/cm2 +/- 3.961, IMR-90 ECM averaged
32.02+/-3.299 µg/cm2, and HDF ECM averaged 34.016 +/- 3.990 µg/cm2. Results were averaged
from three wells of fibroblast-derived matrix solubilized in the same volume. Interestingly, HDF
produce an ECM that has significantly (p=.045) more protein than the other fibroblast-derived
ECM (Figure 4B), thus providing suggesting that there are differences in ECM production
between tissue-specific fibroblasts. After solubilizing, ECM protein was analyzed by SDS-PAGE
and total protein was stained by colloidal blue (Figure 4D). Interestingly, both WI38 and IMR90 derived matrices have more intense Collagen bands (140 kDa- 175 kDa) compared to HDF.
However, HDF-derived ECM has a greater presence of a fibronectin band (260 kDa-280 kDa)
compared to WI38 and IMR90 matrices. Collagen and Fibronectin bands are easily identified
because they have been previously shown to be the prominent constituent of WI38 derived ECM
(Soucy et al., 2009). Also, there appears to be more intermediate protein bands that range
between 175 kDa and 250 kDa that are more prominent in HDF derived ECM than WI38 and
IMR90 ECM. However, it is not possible to conclusively determine the identity these proteins. It
is interesting that there are differences in ECM protein expression between cell lines from two
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distinct tissue sources. These subtle differences in protein expression might alter the phenotype
of lung cancer cell lines, thus potentially affecting the outcome of the human disease.

Figure 4-Fibroblasts and their ECM. (Ai) 5X phase contrast microscopy of fibroblasts. (Aii) 40X
phase contrast microscopy of decellularized fibroblast-derived ECM. (Aiii) Confocal microscopy
of fibroblast-derived ECM with NHS-ester probe. (B) ECM Quantified protein analysis
(µg/cm2), N=3 *p<.05 (TABLE VII). (D) SDS PAGE and Colloidal Blue stain of fibroblastderived ECM. N=3.

B. Fibroblast-derived Matrices Alter Lung Cancer Cell Morphology
The first experiment that was conducted once fibroblast-derived matrices were
successfully produced was to determine how cell morphology changes when lung cancer cells
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were grown on human lung-specific matrix, human dermal matrix, or a normal fibronectin–
coated tissue culture treated dish. Fibronectin-coated dishes were used as a control because it
simulates both the traditional 2D cell culture environment as well as having a natural ECM
component. After fibroblast extraction and ECM purification, A549, H358, and HPL1D cell lines
were seeded onto the fibroblast-derived matrices or FN-coated dish, and then imaged 48 hours
later to determine morphology. Observation by phase-contrast microscopy (Figure 5Ai) revealed
marked differences in cell shape, especially A549 cells. H358 and HPL1D cells exhibited a
slight spindle-shaped morphology. A549 cells showed the biggest change in morphology, thus
were analyzed further quantify the change (figure 5B). Phalloidin, a chemical known to have a
high specificity for filamentous actin, was used to visualize the cytoskeleton of the cell by
confocal microscopy. Simple geometric calculations such as area and perimeter were used to
judge cell circularity (Figure 5C). All three fibroblast-derived matrices significantly (p<.05,
N=10) pressured A549 cells to form a more elliptical shape, instead of a more circular shape
(Circularity = 1), which is exhibited more on fibronectin (Figure 5C). A549 cells on fibronectin
have an average circularity value of .38 +/- .04, while the same cells on WI38, IMR-90, and HDF
ECM have average circularity values of .18 +/- .034 (p=.004), .18 +/- .038 (p=.0023), and .12 +/.019 (p=.0002), respectfully. Cells settled between matrix fibers and elongated according to the
direction of the fibers. However, the type of ECM did not have differential effects on cell
morphology, suggesting that the type and content of the ECM does not induce morphological
change in lung cancer cell lines. Changes in cell morphology can induce drastic alterations in cell
processes such as proliferation and migration, thus influencing the fate of the cancer cells. In
fact, it has been previously reported that cell shape can influence the metastatic capabilities of
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some cancers (Yin et al., 2013). Cell elongation may contribute to increased cell migration. It is
interesting that A549 cells have the most drastic change in morphology, suggesting that this cell
line may have altered growth and migration properties, compared to H358 and HPL1D cells.

Figure 5- Fibroblast-derived ECM alter Lung Cancer Cell Line Morphology. (A) Phase contrast
microscopy photos of A549, H358, and HPL1D cells on FN, WI38 ECM, IMR-90, and HDF
ECM. (B) A549 cells on WI38 ECM stained with Phallodin and DAPI. (C) A549 circularity on
FN and WI38 ECM. N=10. *, p<.05 (TABLE X)
C. Fibroblast-derived Matrices Alter Lung cancer Cell Growth
Next, cell growth alterations due to interaction with the various fibroblast-derived matrices
were examined. Even without employing assays to measure cell number and proliferation, it is
clear by microscopy that human fibroblast-derived matrices affect cell growth, because there are
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simply fewer cells to observe after several doubling times. To test the hypothesis that lung cancer
cells proliferate less when cultured on fibroblast-derived ECM, Alamar Blue™ and cell-counting
assays were used. A549, H358, and HPL1D were seeded onto 12-well plates for Trypan blue™
cell counting, or 96-well plates for an Alamar Blue™ assay, and recorded measurements for four
consecutive days. Trypan blue™ is a dye that stains cells with a disrupted cell membrane, thus it
only accumulates in dead cells. Alternately, Alamar Blue™ is a blue dye that gets reduced to a
purple fluorescent molecule by oxidative reaction in the electron transport chain. Thus Alamar
Blue™ reduction is directly proportional to cellular metabolism. It is clear that both cell density
number (Figure 6A) and subsequent Alamar Blue™ (Figure 6B) metabolism were attenuated
when all cell lines were cultured on all matrices. Cukierman et al. showed that various human
epithelial cancers such as breast and colon cancer cell lines grow slower when cultured on mouse
fibroblast-derived ECM (Serebriiskii et al., 2008). It is the belief in the field that an increased
extracellular matrix presence should enhance cancerous properties. However, this data suggests
that fibroblast-derived ECM inhibit the growth of lung cancer cell lines. Interestingly, a recent
publication has determined that high mechanical strain induces cell cycle entry mediated by Ecadherin (Benham-Pyle et al., 2015). Therefore, this decreased growth could be due to the altered
force the cells experience when cultured on fibroblast-derived matrix. Alternately, perhaps lung
cancer cells lines grow slower on fibroblast-derived ECM because the ECM creates a barrier
between neighboring cells, thus eliminating cell-cell interactions. Nevertheless, more studies are
needed that determine exactly how fibroblast-derived ECM slow down the growth of lung cancer
cell lines, compared to the same cells on a fibronectin-coated tissue culture dish.
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Figure 6- Fibroblast-derived ECM alter Lung Cancer Cell Growth. (A) Manual cell counting.
*,P<.05. (Ai) A549 on all three fibroblast-derived ECM (TABLE XI). (Aii) H358 on all three
fibroblast-derived ECM (TABLE XII). (Aiii) HPL1D on all fibroblast-derived ECM (TABLE
XIII). B: Alamar Blue™*,P<.05. (Bi) A549 on all three fibroblast-derived ECM. (Bii) H358 on
all three fibroblast-derived ECM. (Biii) HPL1D on all fibroblast-derived ECM. N=3. *, Pvalue<.05 (TABLE XIV-XVI)
D. Fibroblast-Derived Matrices alter functional protein levels of lung cancer cell lines
To perhaps understand which growth-related signaling pathways are attenuated when
A549 cells interact with various fibroblast-derived ECM, western blot analysis was performed.
Western blotting is a common analytical technique that uses antibodies to detect specific protein
levels in a cell lysate. Here, A549 cells cultured on FN, WI38 ECM, IMR-90 ECM, and HDF
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ECM were lysed, spilling out soluble protein. Antibodies specific for proteins involved in
MAPK signaling, Epithelial-to-Mesenchymal Transition (EMT) signaling, as well other proteins
known to be involved in cellular proliferation were utilized to help understand why A549 cells
have restricted growth when cultured on all fibroblast-derived matrices. Interestingly, many
proteins and phosphorylated proteins are decreased at the protein level, as detected by western
blot (Figure 7). Phosphorylated MAPK family members such as P38 and P44/42 are decreased
when A549 cells are cultured on all fibroblast-derived ECM (Figure 7B). MAPK initiation is
known to activate many downstream pathways that affect cell cycle entry and cell growth (Segar
et al., 1995). Similarly, AKT, Cyclic-AMP Response Element Binding (CREB) protein, and
Mammalian-Target of Rapamycin (MTOR), which are all together involved in several cascades
that regulate cell cycle, are decreased when A549 cells are cultured on all fibroblast-derived
matrices (Figure 7A and 7B). Also, CDC42, a known cell cycle regulator, and phosphorylated
SRC kinase, a known oncogene in lung cancers, are decreased on fibroblast-derived ECM. These
data suggest possible effector molecules that are disrupted when A549 cells are cultured on
fibroblast-derived ECM, thus providing key insight into the effect of the ECM on lung cancer
cell line growth.
As previously stated, metastatic lung cancer is the deadliest and most aggressive form of
the disease. EMT is a process initiated by cells in the primary tumor in order to migrate and
become metastatic. Biomarkers of EMT are the loss of E-cadherin, and the gain on Vimentin
expression in epithelial cancers (Xiao et al., 2010). It is hypothesized that ECM can influence
EMT biomarkers, thus inducing cells to undergo EMT. Interestingly, E-cadherin expression is
greatly decreased and Vimentin expression is a slightly increased when A549 cells are cultured
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on all fibroblast-derived matrices. These data suggest that fibroblast-derived ECM alter EMT
markers of A549 cells, which could induce a more migratory phenotype, thus increasing
likelihood of metastasis.

Figure 7- Fibroblast-derived ECM alters Protein Levels of A549 Cells. (A) Western blot of AKT,
pAKT, pCREB, pSRC, total SRC, and GAPDH. (B) Western blot of mTOR, PhosphorylatedmTOR, P44/42, Phosphorylated P44/42, p38, Phosphorylated p38, CDC42, and GAPDH. (C)
Western blot of Vimentin, E-cadherin, and GAPDH.
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E. Fibroblast Derived Matrices Do not alter Drug Resistance of Lung Cancer Cell Lines
Cancer cells grown in three dimensions, such as in Matrigel™, or in a spheroid-forming
medium, experience epigenetic changes that alter cancer phenotype. Three dimensional cell
culture gives the cell line a TME that influences its response to drug treatment. Similarly, the
human TME helps cancer cells evade drug-induced cell death. It was hypothesized that because
human lung fibroblast-derived ECM alter lung cancer cell line morphology and growth rates,
then it was reasonable to assume drug response would also change. To test this, lung cancer cells
cultured on human lung fibroblast-derived ECM were treated with various chemotherapeutic
agents often used in the clinic to treat lung cancer patients. Interestingly, culturing A549, H358,
and HPL1D cells on WI38 ECM did not alter the dose response of Cisplatin and Gemcitabine
(Figure 8A-C), which are common first-line therapies for lung cancer patients. Perhaps these
drugs are so cytotoxic that the ECM has little or no effect. However, this model could still be
beneficial for future drug studies. For instance, if there is an alteration in a certain drug response
on fibroblast-derived ECM, it could provide evidence that the certain therapy is affected by the
ECM, which could serve as an indicator of its efficacy in an in vivo setting.
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Figure 8- Fibroblast-derived ECM do does not alter drug response to Gemcitabine and Cisplatin.
(A) A549 on WI38 ECM. (B) H358 on WI38 ECM. (C) HPL1D on WI38 ECM. N=3. Not
significant (p>.999).

F. Fibroblast Derived Matrices Protect Lung Cancer Cells from Serum Deprivation
Although the drug response of lung cancer cell lines is not affected by human fibroblastderived ECM, other experiments to test the ability of lung cancer cell lines to survive stressful
environments when cultured on ECM, such as serum withdrawal, were explored. Serum
deprivation induces cellular apoptosis by mitochondrial outer membrane permealibilzation
(MOMP) in colorectal cancer cells (Braun et al., 2011). Although many cancer cells evade
apoptosis by inhibiting MOMP, many cancer cell lines cannot survive prolonged exposure to
serum-free media. However, little is known about how the ECM affects serum dependability. It
is hypothesized that proteins and growth factors present in the fibroblast-derived ECM can
sustain lung cancer cells in an otherwise nutrient-free environment. To test the effects of serum
depletion on cells on and off fibroblast-derived ECM, cells were seeded in complete media for
24 hours to allow cells to adhere, media was then removed and cells were washed with PBS, and
replenished with serum-free media. Observation by phase contrast microscopy revealed that 48
hours after the removal of serum from the media, there are more A549 cells on ECM compared

27

to a fibronectin dish, suggesting that the ECM supports cell adhesion and perhaps growth in the
absence of serum (Figure 9D). To determine the difference between cell growth on ECM and
fibronectin, Alamar Blue™ metabolism was followed each day. All lung cancer cell lines
cultured on both human lung and human dermal fibroblast-derived ECM showed an increase in
relative viable cells compared to the same cell lines grown on fibronectin plates (Figure 9A, 9B,
and 9C). A549 survive serum deprivation the best by Alamar Blue™ (figure 9A), until day 4.
HPL1D and H358 cells also tolerated serum withdrawal well until day 4 (Figure 9A, 9B).
However, The ECM was not able to sustain cell viability without serum past four days. Perhaps
this is due to degradation of the ECM and its growth factors by the lung cancer cell lines. Also,
A549 cells cultured on ECM did not change morphology when cultured in serum-free media
(Figure 9B), whereas as A549 cells on Fibronectin-coated dish appeared rounded and unhealthy
(Figure 9A). Upon western blot analysis, it was clear that fibroblast-derived ECM rescues serum
deprivation-induced apoptosis by evading p21 expression and by upregulating BCL-xL
expression (Figure 9F). p21, is a cyclin-dependent kinase inhibitor that is known to promote cellcycle arrest and apoptosis in serum-free conditions (Braun et al., 2011). Interestingly, BCL-xL,
an anti-apoptotic protein that protects cells against apoptosis, is slightly increased when A549
cells are cultured on fibroblast-derived ECM with and without serum (figure 9F), thus suggesting
it plays a role in the survival of A549 cells in serum-free conditions. These results suggest that
the ECM is capable of providing a cell-survival stimulus when the plethora of growth factors and
nutrients available in FBS are absent. This observation might be important in understanding how
lung adenocarcinoma cells survive in the inner-most core of a solid tumor, where nutrients, as
well as oxygen, from the blood supply are scarce.
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Figure 9- Fibroblast-derived ECM Protects Lung Cancer Cell Lines from Serum Deprivation.
(A) A549, H358, and HPL1D cells on fibronectin in serum-free media for 48 hours. (B) A549,
H358, and HPL1D cells on WI38 ECM in serum-free media for 48 hours. (C) Relative cell
growth of A549 cells. (D) Relative cell growth of H358 cells. (E) Relative cell growth of HPL1D
cells. (F) Western blot of serum deprived cells after 48 hours. *,p<.05 (TABLE IV-VI)
G. Fibroblast-Derived Matrices Change mRNA levels of Various Genes in Lung Cancer
Cells
It is clear that human lung fibroblast-derived ECM alters many processes that influence
behaviors like morphology, growth, and serum-deprivation survival. However, little is known
about how fibroblast-derived ECM alters the regulation of gene transcription. Transcription
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regulation is an extremely important process that influences cellular phenotypes. Therefore, an
experiment was designed to determine the effect of gene transcription when A549 and H358
cells interact with human fibroblast-derived ECM. A microarray was used to determine the
difference of messenger-RNA (mRNA) copy number when lung cancer cell lines were cultured
on fibroblast-derived ECM. MRNA is the result of a transcribed gene, awaiting ribosome entry
to be translated into an amino acid sequence, which is then folded to the proper native protein
structure. Although mRNA quantity does not directly dictate functional protein quantity, it is
directly connected with how much DNA is transcribed. To test the change in mRNA copy
number in lung cancer on human fibroblast-derived ECM, A549 and H358 cell lines were
cultured for 48 hours on WI-38 ECM, IMR-90 ECM, and Fibronectin-coated plastic. Briefly,
RNA was extracted, converted to DNA, labeled, hybridized, and scanned for hybridization
quantification. Data was then analyzed by Sabine Waigel and the UofL genomics core facility. A
heat map was generated (Figure 10A) to show an unrefined interpretation of each gene probe
intensity that was significant changed compared to a fibronectin-coated dish (P-value <.05 and
fold change greater than 1.5). It is clear by examining the heat map that there are many gene
probes that differ in expression induced by fibroblast-derived ECM. In total, 182 target
sequences, which corresponded to 114 gene changes, were shared between both cells lines on
both fibroblast-derived ECM compared to fibronectin. Affected Gene IDs were uploaded into
Metacore™ for Gene Ontology (GO) analysis. Metacore™ GO process analysis identifies
canonical and non-canonical pathways that are likely to be affected by a cluster of significantly
changed genes. Top ranked potentially affected pathways include complement-mediated
immunity, cytoskeletal remodeling, and ECM remodeling (Figure 10B).
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Interestingly, 87 of

these significant gene changes were down-regulated, and only 27 were upregulated. Many downregulated genes coded for proteins that constitute the extracellular matrix, suggesting that when
cells are in contact with adequate ECM, they decrease transcription of genes that code for ECM
proteins such as fibrinogen alpha, fibrinogen beta, collagen type 4, collagen type5, and villin
(Table 2). Also, MMP7, which is a protease that degrades Collagen and Fibronectin, is also
down-regulated. The most down-regulated gene, LGALS2 belongs to a family of galectins,
which can serve as interacting proteins with ECM proteins and can be deregulated in some
cancers, including lung cancer (Liu et al., 2005; Buttery et al., 2004). Also, several genes that
regulate the complement-mediated immunity pathway, such as C3, C1S, and bradykinin, are
down-regulated when both lung cancer cell lines are cultured on WI38 and IMR90 ECM (Table
2). Complement-mediated immunity pathways have been shown to be activated in lung cancer
(Pio et al., 2014). Interestingly, Galectin expression affects also complement activation (Pio et
al., 2013). Up-regulated genes include NT5E, IL-8, KCNMA1, BCAT1, ASNS, stanniocalcin-2,
and PSAT1 (Table 3). Interestingly. IL-8 is known to promote angiogenesis, thus supporting
previous research by Patricia Soucy, suggesting a role for ECM in angiogenesis (Luppi et al.,
2007; Soucy et al., 2015; Soucy et al., 2009). NT5E, which is also known as ecto-5’nucleotidase, has been shown to be upregulated in lung and breast cancers where it decreases
patient survival rates by attenuating immune responses and promoting environments for
vascularization and metastasis ( Zhang et al., 2010; Jin et al., 2010). KCNMA1, a gene that
reported four probes that had significant expression changes, codes for a protein that complexes
to form potassium and calcium ion channels (Table 3). KCNMA1 ion channels have been shown
to be more present in metastatic breast cancer cells but little is known of its role in lung cancer
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(Khaitan et al., 2009). The ECM is a key player in the initiation of breast cancer cells into
metastasis. This result that KCNMA1 mRNA is increased when lung cancer cells are cultured on
fibroblast-derived ECM might suggest that ECM can induce KCNMA1 to play a protumorigenic role in lung cancer cells. Similarly, stanniocalcin-2, a gene that had three probes
reported from the microarray data, also plays a role calcium regulation, and is also overexpressed
in lung cancer and impairs a poor prognosis (Na et al., 2015). ASNS, BCAT1, and PSAT1 all
code for enzymes that regulate amino acid synthesis, thus directly affecting cell growth and
proliferation. These microarray data reveals the complex mechanisms that the ECM can regulate
within lung cancer cells. Thus providing strong evidence that Fibroblast-derived ECM can
potentiate the phenotype of lung cancer cell lines.

Figure 10- Fibroblast-derived ECM alters mRNA profile of A549 and H358 Cells. (A) heat map
of common significant (fold change >1.5 and P-Value<.05). (B) Gene Ontology (GO) Processes.
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To validate the microarray results, primers were designed to bind only to the mRNA
region of various hits from the microarray data. Separate samples were analyzed to confirm the
results. QPCR analysis (figure 11) revealed that indeed, mRNA that was altered on the
microarray are also being altered in separate biological replicates. Further, the direction of the
fold changes were shared between microarray data and qPCR, thus giving confidence in the
highly sensitive microarray data.
TABLE II
COMMON RANKED DOWN-REGULATED GENES BETWEEN A549 AND H358
CELLS ON WI38 AND IMR-90 ECM
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TABLE III
COMMON RANKED UP-REGULATED GENES BETWEEN A549 AND H358
CELLS ON WI38 AND IMR-90 ECM

Figure 11- Fold Change of mRNA by Quantitative qPCR
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H. Fibroblast-Derived Matrices can Induce Lung Cancer Cells to Migrate
In order to test how human fibroblast-derived ECM affects cellular migration, which is a
critical mechanism that lung cancer cells utilize to invade and metastasize, a simple experiment
was designed employing a trans-well chamber assay. A trans-well chamber is a tissue culture
device that has 0.8 µm pores that allow actively migrating cells to pass through to the bottom.
Trans-well chambers are used to model migratory and invasive properties of cells. Many cancer
cell biologists employ such chambers to test whether migration is altered following a given
treatment. Here, trans-well chambers were used as a substrate to grow ECM, which was then
used to recruit lung cancer cells. It is hypothesized that human fibroblast-derived ECM could act
as a chemoattractant that could recruit lung cancer cell lines to its side of the Trans-well
chamber. Clearly, all fibroblast-derived ECM act as a chemoattractant for a549 cells and induce
them to migrate across the chamber (figure 12A). Upon counting, Three times the number of
A549 cells were migratory when fibroblast-derived ECM was present, compared to fibronectin.
Also, it is clear visually by Hemotoxylin and Eosin staining that more A549 migrated to the
fibroblast-derived ECM (Figure 12B). Cell migration is an important process that affects both
wound healing and cancer progression. In cancer, local as well as distal ECM environments are
equally as important in understanding cancer cell invasion and metastasis. Therefore,
incorporation of fibroblast-derived ECM into trans-well migration could provide researchers
with a better model to study cancer cell migration.
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Figure 12- Fibroblast-derived ECM alter Cell Migration of Lung Cancer Cell Lines in a
Trans-well Chamber. (A) Average migratory cells per field (4 fields). *, p<.05 (TABLE XIX)
It is clear from microscopic observation that lung cancer cell lines on fibroblast-derived
ECM do not grow in large clusters like the same cells on fibronectin. It was postulated that cells
grown on the 3D fibers of the ECM exhibit migration along the fibers, thus spreading the cells
apart from each other. To test this type of migration, A549, H358 and HPL1D cells were seeded
onto fibroblast-derived matrices and after 24 hours, and transferred into a live cell microscopy
chamber for time lapse imaging (Figure 13). Time lapse shows that cells grown on fibroblastderived matrix exhibit more migration than on a fibronectin-coated dish. A549, H358, and
HPL1D cells all migrated farther distances on fibroblast-derived ECM than on Fibronectin
(Figure 13A). Cells were tracked for between 4 and 8 hours (Figure 13A). It is clear that A549,
H358 and HPL1D cells migrate farther distances in 4-8 hours when cultured on fibroblastderived ECM. To characterize this, directionality (D/d) (Figure 13B) is calculated to determine
the linearity of the directional migration (Figure 13C). Evidently, A549, H358, and HPL1D cell
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lines exhibited a more directional migration on fibroblast-derived ECM compared to control.
Also, it is clear by calculating distance traveled by time traveled that the velocity of the cells on
fibroblast-derived ECM is greater than the same cells on fibronectin (Figure 13D). It appears
that when the lung cancer cell lines interact with a fiber, they travel along that fiber only, rarely
migrating towards adjacent fibers. This result will be important for future cell migration studies,
encouraging researchers to use ECM that are highly aligned. Cell migration properties are highly
adopted in lung cancer cells, which allow them to invade accessible organs. These data indicate
that the interaction between fibroblast-derived ECM and lung cancer cell lines induce a
migratory phenotype. It is interesting that fibroblast-derived ECM alters EMT properties, thus
suggesting that the ECM plays a role in EMT induction. Therefore, fibroblast-derived matrices
should be used in the future to study ECM-induced EMT.
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Figure 13- Fibroblast-derived ECM induce Directional Migration. (A) Resultant timelapse tracks of A549, H358, and HPL1D on WI38 ECM. (B) Depiction of Directionality= D/d.
(C) Calculated Directionality A549 p=.033, H358 p=.0067, HPL1D p=.0002). N=7. (D) Average
velocity of migrated cells (µm/hour) N=7. A549, H358, HPL1D p<.0001.

I. Fibroblast-derived ECM increase Subcutaneous Xenograft Tumor Formation in Mice
Previously, researchers have mixed cancer cells with Matrigel™ and implant them into
the subcutaneous tissue of mice to study tumor development with an extracellular matrix
component (Bao et al., 1994). To determine if fibroblast-derived matrix proteins could illicit a
similar pro-tumorigenic response, fibroblast-derived ECM was scraped in ice cold PBS and
mixed with cells. The same ECM-to-cell ratio of 26,000 cells/cm2 that was used in vitro was
used in vivo. A549 cells and matrix orA549 cells without matrix were injected into the
subcutaneous tissue of 3 month old NRG mice and let incubate for 60 days. NRG mice are a new
breed of mice that harbor mutations in NOD, RAG, and Interleukin-2 gamma receptor, which
eliminates the immune system of T and B cells, thus allowing for xenografts without an immune
response. A549 cells cultured with the scraped fibroblast-derived ECM grew larger tumors by
calculated volume than a549 cells with PBS (figure 14). However, these data are not statically
significant, with a p-value of 0.07 (Figure 14C) Further, tumors with ECM showed increased
mass (Figure 14D). Although A549 cells mixed with ECM formed larger tumors, hemotoxylin
and Eosin staining revealed little differences in the morphology of the tumors (Figure 14Ei and
14Eii). A pathologist might be able to determine differences in the tumor sections, but little is
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noticeable to the untrained eye. Although fibroblast-derived ECM decreased lung cancer cell line
growth in vitro, it appears that they it enhance tumor formation in vivo. It could be that in the in
vivo experiments, the native architecture of the fibroblast-derived ECM that is present in vitro is
absent, thus allowing for unrestricted growth. Further, the same survival signals that the lung
cancer cell lines exploit from the ECM in vitro when cultured in serum free conditions may be
providing growth signals in A549 xenograft. These data are important in elucidating the role of
ECM architecture, as well as its composition in cancer signaling.

Figure 14- Fibroblast-derived ECM Increase Subcutaneous Tumor Formation of A549
Cells in Mice. Ai: in vivo A549 with ECM Xenograft. Aii: in vivo A549 with PBS Xenograft. Bi:
Picture of removed tumor with ECM. Bi: Picture of removed tumor with PBS. C: Calculated
volumes of A549 xenografts with and without ECM (p=.07) D: Measured mass (g) of excised
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tumors. Ei: 1X picture of A549 Xenograft with ECM with 20X expanded view. Eii: 1X picture
of A549 Xenograft with PBS with 20X expanded view. N=13. *,p=.026.
IV. Conclusions and Future Directions
This work shows that human fibroblast-derived extracellular matrix alters cell
morphology, cell growth, proliferation, mRNA expression, functional protein expression, and
migration properties of the A549, H358, and HPL1D lung cancer cell lines. It is clear that when
cultured on human fibroblast-derived ECM, lung cancer cell lines have less activated MAPK
protein expression as well as mTOR and cell cycle regulating pathways, which might contribute
to their attenuated growth. Also, lung cancers have altered expression of ECM protein-coding
and complement-mediated immunity genes, thus affecting many downstream pathways. As
discovered by western blot, lung cancer cell lines also develop an EMT phenotype, which could
be responsible for their increased migration. Interestingly, ECM harvested from different
fibroblast cell lines originating from different human tissues did not have a noticeable effect in
this work. Perhaps a less harsh decellularization technique will leave behind a more unique
ECM, thus allowing researchers to better mimic the natural ECM. This work is significant
because it provides further evidence that the extracellular matrix has a strong effect on the
phenotype of lung cancer cells, which needs to be further studied to successfully treat the entire
tumor microenvironment.
In future work, scientists will attempt to alter the influence of the extracellular matrix on
lung cancer cells. For instance, the age of an organism significantly increases the probability of
cancer and it is known that cancer vulnerability can be influenced by the extracellular matrix.
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Fibroblast-derived matrix procured from old and young fibroblasts could differentially regulate
the growth and migration properties of lung cancer cells. Also, future researchers could
successfully overexpress oncogenes or knock down tumor suppressors in human lung or dermal
fibroblasts and determine their matrix components and subsequent effect on lung cancer cell
lines. Further, to expand research in different focus groups, future researchers could examine
how the ECM affects leukemia cells with regards to homing and drug resistance. This future
work could provide valuable knowledge of the feedback mechanism that exists between cancer
and its extracellular matrix.
V. Appendix
TABLE IV
A549 SERUM DEPRIVATION STATISTICAL ANALYSIS
A549 Serum deprivation
Number of families
4
Number of comparisons per
6
family
Alpha
0.05
Tukey's multiple
comparisons test
Row 1
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

Mean
Diff.

95% CI of diff.

0 -0.09736 to
0.09736
1.99E- -0.09736 to
08 0.09736
0 -0.09736 to
0.09736
1.99E- -0.09736 to
08 0.09736
0 -0.09736 to
0.09736
-2E-08 -0.09736 to
0.09736
41

Summary Adjusted P
Value

ns

> 0.9999

ns

> 0.9999

ns

> 0.9999

ns

> 0.9999

ns

> 0.9999

ns

> 0.9999

Row 2
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

Row 3
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

Row 4
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

-0.566 -0.6634 to 0.4687
-0.4437 -0.5411 to 0.3463
-0.5542 -0.6516 to 0.4569
0.1223 0.02496 to
0.2197
0.01178 -0.08558 to
0.1091
-0.1105 -0.2079 to 0.01318

****

< 0.0001

****

< 0.0001

****

< 0.0001

-0.3626 -0.4600 to 0.2653
-0.3496 -0.4470 to 0.2523
-0.3315 -0.4289 to 0.2342
0.01299 -0.08437 to
0.1103
0.03112 -0.06624 to
0.1285
0.01813 -0.07923 to
0.1155

****

< 0.0001

****

< 0.0001

****

< 0.0001

-0.1861 -0.2834 to 0.08870
-0.159 -0.2563 to 0.06161
- -0.1869 to
0.08953 0.007827
0.02709 -0.07027 to
0.1244
0.09652 -0.0008332 to
0.1939
0.06944 -0.02792 to
0.1668

****
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**

0.0093

ns

0.9876

*

0.0211

ns

0.9835

ns

0.8222

ns

0.9574

< 0.0001

***

0.0006

ns

0.0805

ns

0.8744

ns

0.0527

ns

0.2351

TABLE V
H358 SERUM DEPRIVATION STATISTICAL ANALYSIS
H358 Serum Deprivation
Number of families
4
Number of comparisons per
6
family
Alpha
0.05
Tukey's multiple comparisons
test
Row 1
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM
Row 2
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

Row 3
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM

Mean
Diff.

-2E-08
-2E-08
2E-08
0
4E-08
4E-08

95% CI of diff.

Significant? Adjusted P
Value

-0.2692 to 0.2692
-0.2692 to 0.2692
-0.2692 to 0.2692
-0.2692 to 0.2692
-0.2692 to 0.2692
-0.2692 to 0.2692

No
No
No
No
No
No

> 0.9999
> 0.9999
> 0.9999
> 0.9999
> 0.9999
> 0.9999

-0.3225 -0.5918 to 0.05327
-0.271 -0.5402 to 0.001707
-0.5012 -0.7705 to -0.2320
0.05156 -0.2177 to 0.3208
-0.1787 -0.4480 to
0.09053
-0.2303 -0.4995 to
0.03897

Yes

0.0139

Yes

0.0481

No

0.1153

-0.3275 -0.5967 to 0.05824
-0.2891 -0.5584 to 0.01988
-0.2195 -0.4887 to
0.04979
0.03836 -0.2309 to 0.3076
0.108 -0.1612 to 0.3773

Yes

0.0122

Yes

0.0315

No

0.1427

No
No

0.9801
0.6998
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Yes
No
No

< 0.0001
0.954
0.2927

WI38 ECM vs. HDF ECM
Row 4
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

0.06967 -0.1996 to 0.3389

No

0.8959

-0.0809 -0.3501 to 0.1883
-0.1447 -0.4140 to 0.1245
-0.2083 -0.4776 to
0.06093
-0.0638 -0.3331 to 0.2054
-0.1274 -0.3966 to 0.1418
-0.0636 -0.3328 to 0.2057

No
No
No

0.8473
0.4748
0.176

No
No
No

0.9174
0.5807
0.9183

TABLE VI
HPL1D SERUM DEPRIVATION STATISTICAL ANALYSIS
HPL1D Serum Deprivation
Number of families
4
Number of comparisons per
6
family
Alpha
0.05
Tukey's multiple
comparisons test
Row 1
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

Row 2
FN vs. IMR90 ECM

Mean
Diff.

95% CI of diff.

Significant? Adjusted P
Value

-2E-08 -0.1039 to
0.1039
-2E-08 -0.1039 to
0.1039
-2E-08 -0.1039 to
0.1039
0 -0.1039 to
0.1039
0 -0.1039 to
0.1039
0 -0.1039 to
0.1039

No

> 0.9999

No

> 0.9999

No

> 0.9999

No

> 0.9999

No

> 0.9999

No

> 0.9999

-0.1468 -0.2508 to -

Yes
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0.003

FN vs. WI38 ECM

-0.1686

FN vs. HDF ECM

-0.2119

IMR90 ECM vs. WI38 ECM

-0.0218

IMR90 ECM vs. HDF ECM

-0.06514

WI38 ECM vs. HDF ECM

-0.04334

Row 3
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

Row 4
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

0.04287
-0.2726 to 0.06466
-0.3159 to 0.1080
-0.1257 to
0.08215
-0.1691 to
0.03881
-0.1473 to
0.06061

Yes
Yes

0.0006
< 0.0001

No

0.9408

No

0.3414

No

0.6743

-0.3222 -0.4261 to 0.2182
-0.3179 -0.4218 to 0.2139
-0.3933 -0.4973 to 0.2894
0.004302 -0.09964 to
0.1082
-0.07113 -0.1751 to
0.03282
-0.07543 -0.1794 to
0.02852

Yes

< 0.0001

Yes

< 0.0001

Yes

< 0.0001

-0.1735 -0.2774 to 0.06951
-0.2279 -0.3319 to 0.1240
-0.1141 -0.2181 to 0.01020
-0.05446 -0.1584 to
0.04949
0.05931 -0.04463 to
0.1633
0.1138 0.009828 to
0.2177

No

0.9995

No

0.2678

No

0.2219

Yes

0.0004

Yes
Yes

0.027

No

0.4968

No

0.423

Yes

0.0276

TABLE VII
ECM PROTEIN STATISTICAL ANALYSIS
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< 0.0001

ECM Protein
Number of families
Number of comparisons per
family
Alpha

1
3
0.05

Tukey's multiple
comparisons test

Mean
Diff.

WI38 ECM vs. IMR-90
ECM
WI38 ECM vs. HDF ECM

0.04534 -1.902 to 1.992

IMR-90 ECM vs. HDF ECM

95% CI of diff.

-1.953 -3.900 to 0.005657
-1.998 -3.945 to 0.05100

Summary Adjusted P
Value
ns

0.9972

*

0.0495

*
0.0453

TABLE VIII
TIME-LAPSE STATISTICAL ANALYSIS
Time-lapse Migration Velocity
Number of families
Number of comparisons per family
Alpha

1
15
0.05

Tukey's multiple comparisons test

Mean
Diff.

95% CI of diff.

Summary

A549 FN vs. A549 WI38
A549 FN vs. H358 FN
A549 FN vs. HPL1D FN
A549 WI38 vs. H358 FN
A549 WI38 vs. H358 WI38
A549 WI38 vs. HPL1D FN
A549 WI38 vs. HPL1D WI38
H358 FN vs. H358 WI38
H358 FN vs. HPL1D FN
H358 WI38 vs. HPL1D WI38

-26.64
1.734
-3.643
28.37
3.07
23
0.2967
-25.3
-5.377
-2.773

-35.96 to -17.32
-7.590 to 11.06
-12.97 to 5.680
19.05 to 37.70
-6.254 to 12.39
13.67 to 32.32
-9.027 to 9.620
-34.63 to -15.98
-14.70 to 3.947
-12.10 to 6.550

****
ns
ns
****
ns
****
ns
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Adjusted
P Value

< 0.0001
0.993
0.8454
< 0.0001
0.918
< 0.0001
> 0.9999
**** < 0.0001
ns
0.5187
ns
0.9453

HPL1D FN vs. HPL1D WI38

-22.7

-32.02 to -13.38

****

< 0.0001

TABLE IX
DIRECTIONALITY STATISTICAL ANALYSIS
Directionality
Number of families
Number of comparisons
per family
Alpha

1
15
0.05

Tukey's multiple
comparisons test

Mean
Diff.

A549 FN vs. A549 WI38

-0.3031 -0.5907 to 0.01558
0.03643 -0.2511 to
0.3240
-0.3244 -0.6120 to 0.03687
0.1072 -0.1804 to
0.3947
-0.3624 -0.6499 to 0.07483
0.3396 0.05201 to
0.6271
-0.02129 -0.3088 to
0.2663
0.4103 0.1227 to

A549 FN vs. H358 FN
A549 FN vs. H358 WI38
A549 FN vs. HPL1D FN
A549 FN vs. HPL1D
WI38
A549 WI38 vs. H358 FN
A549 WI38 vs. H358
WI38
A549 WI38 vs. HPL1D

95% CI of
diff.
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Significant
?

Summar
y

Adjusted P
Value

Yes

*

0.0336

No

ns

0.9989

Yes

*

0.019

No

ns

0.8735

Yes

**

0.0064

Yes

*

0.0124

No

ns

Yes

**

> 0.9999
0.0015

FN
A549 WI38 vs. HPL1D
WI38
H358 FN vs. H358 WI38

-0.05925

H358 FN vs. HPL1D FN

0.07072

H358 FN vs. HPL1D
WI38
H358 WI38 vs. HPL1D
FN
H358 WI38 vs. HPL1D
WI38
HPL1D FN vs. HPL1D
WI38

-0.3988

-0.3609

0.4316
-0.03796
-0.4695

0.6978
-0.3468 to
0.2283
-0.6484 to 0.07330
-0.2168 to
0.3583
-0.6864 to 0.1113
0.1440 to
0.7191
-0.3255 to
0.2496
-0.7571 to 0.1820

No

ns

0.9893

Yes

**

0.0067

No

ns

0.9765

Yes

**

0.0021

Yes

***

0.0008

No

ns

0.9987

Yes

***

0.0002

TABLE X
CIRCULARITY STATISTICAL ANALYSIS
Cell Circularity
Number of families
Number of comparisons per
family
Alpha

1
6
0.05

Tukey's multiple
comparisons test

Mean
Diff.

A549 FN vs. A549 WI38

0.196 0.05046 to
0.3414
0.2074 0.06186 to
0.3528

A549 FN vs. A549 IMR-90

95% CI of
diff.
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Significant
?

Summar
y

Adjusted P
Value

Yes

**

0.0043

Yes

**

0.0023

A549 FN vs. A549 HDF

0.2528 0.1073 to
0.3982

Yes

***

0.0002

TABLE XI
A549 CELL COUNTING STATISTICAL ANALYSIS
A549 Count
Within each row, compare columns (simple effects within rows)
Number of families
Number of comparisons per
family
Alpha
Tukey's multiple comparisons
test
Row 1
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF
WI38 ECM vs. HDF

Row 2
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF

4
6
0.05
Mean
Diff.

95% CI of diff.

Significant? Adjusted P
Value

2667 -43697 to
49030
6000 -40364 to
52364
1000 -45364 to
47364
3333 -43030 to
49697
-1667 -48030 to
44697
-5000 -51364 to
41364

No

0.9986

No

0.9849

15667 -30697 to
62030
21333 -25030 to
67697
14667 -31697 to
61030
5667 -40697 to
52030
-1000 -47364 to
45364
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No

> 0.9999

No

0.9973

No

0.9997

No

0.9911

No

0.7967

No

0.6026

No

0.8266

No

0.9872

No

> 0.9999

WI38 ECM vs. HDF

-6667 -53030 to
39697

Row 3
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF
WI38 ECM vs. HDF

Row 4
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF
WI38 ECM vs. HDF

No

0.9796

51667 5303 to 98030
60000 13636 to
106364
50000 3636 to 96364
8333 -38030 to
54697
-1667 -48030 to
44697
-10000 -56364 to
36364

Yes
Yes

0.0243
0.0071

Yes
No

0.0306
0.9614

No

0.9997

No

0.9361

143333 96970 to
189697
136667 90303 to
183030
165000 118636 to
211364
-6667 -53030 to
39697
21667 -24697 to
68030
28333 -18030 to
74697

Yes

< 0.0001

Yes

< 0.0001

Yes

< 0.0001

No

0.9796

No

0.5905

No

0.3631

TABLE XII
H358 CELL COUNTING STATISTICAL ANALYSIS
H358 Count
Number of families
Number of comparisons per
family
Alpha

4
6
0.05
95% CI of diff.

Tukey's multiple
comparisons test

Mean Diff.
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Significant? Adjusted P
Value

Row 1
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF
WI38 ECM vs. HDF

4000
2000
5000
-2000
1000
3000

Row 2
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF

16500
11000
9500
-5500
-7000

WI38 ECM vs. HDF

-1500

Row 3
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF
WI38 ECM vs. HDF
Row 4
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF

45771
31771
16771
-14000
-29000
-15000

195000
185000
155000
-10000
-40000

-97833 to 105833
-99833 to 103833
-96833 to 106833
-103833 to 99833
-100833 to
102833
-98833 to 104833

No
No
No
No
No

0.9996
> 0.9999
0.9991
> 0.9999
> 0.9999

No

0.9998

-85333 to 118333
-90833 to 112833
-92333 to 111333
-107333 to 96333
-108833 to 94833
-103333 to
100333

No
No
No
No
No
No

0.9712
0.9911
0.9942
0.9989
0.9977
> 0.9999

-56062 to 147604
-70062 to 133604
-85062 to 118604
-115833 to 87833
-130833 to 72833
-116833 to 86833

No
No
No
No
No
No

0.6204
0.8324
0.9699
0.982
0.8667
0.9781

93167 to 296833
83167 to 286833
53167 to 256833
-111833 to 91833
-141833 to 61833
-131833 to 71833

Yes
Yes
Yes
No
No
No

< 0.0001
0.0001
0.0013
0.9933
0.7133
0.8547

TABLE XIII
HPL1D CELL COUNTING STATISTICAL ANALYSIS
HPL1D Count
Number of families
Number of comparisons per
family
Alpha

4
6
0.05
51

Tukey's multiple
comparisons test
Row 1
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF
WI38 ECM vs. HDF

Row 2
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF
WI38 ECM vs. HDF

Row 3
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF

Mean
Diff.

95% CI of
diff.

Significant
?

Summar
y

-500 -20871 to
19871
4000 -16371 to
24371
-1000 -21371 to
19371
4500 -15871 to
24871
-500 -20871 to
19871
-5000 -25371 to
15371

No

ns

0.9999

No

ns

0.9506

No

ns

0.9991

No

ns

0.9318

No

ns

0.9999

No

ns

0.9094

8000 -12371 to
28371
9000 -11371 to
29371
2000 -18371 to
22371
1000 -19371 to
21371
-6000 -26371 to
14371
-7000 -27371 to
13371

No

ns

0.7135

No

ns

0.6331

No

ns

0.9933

No

ns

0.9991

No

ns

0.8548

No

ns

0.7885

67000 46629 to
87371
55500 35129 to
75871
57500 37129 to
77871
-11500 -31871 to
8871
-9500 -29871 to

Yes

****

< 0.0001

Yes

****

< 0.0001

Yes

****

< 0.0001

No

ns

0.4323

No

ns

0.5921
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Adjusted P
Value

10871
2000 -18371 to
22371

WI38 ECM vs. HDF

Row 4
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF
WI38 ECM vs. HDF

160000 139629 to
180371
115000 94629 to
135371
120000 99629 to
140371
-45000 -65371 to 24629
-40000 -60371 to 19629
5000 -15371 to
25371

No

ns

0.9933

Yes

****

< 0.0001

Yes

****

< 0.0001

Yes

****

< 0.0001

Yes

****

< 0.0001

Yes

****

< 0.0001

No

ns

0.9094

TABLE XIV
A549 ALAMAR BLUE STATISTICAL ANALYSIS
A549 Alamar blue
Within each row, compare columns (simple effects within rows)
Number of families
Number of comparisons per
family
Alpha
Tukey's multiple
comparisons test
Row 1
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM

4
6
0.05
Mean
Diff.

95% CI of diff.

1.987E-08 -0.03641 to
0.03641
-1.987E- -0.03641 to
08 0.03641
1.987E-08 -0.03641 to
0.03641
-3.974E- -0.03641 to
08 0.03641
0 -0.03641 to
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Significant? Adjusted P
Value

No

> 0.9999

No

> 0.9999

No

> 0.9999

No

> 0.9999

No

> 0.9999

WI38 ECM vs. HDF ECM

Row 2
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

Row 3
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

Row 4
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

0.03641
3.974E-08 -0.03641 to
0.03641

No

> 0.9999

0.09386 0.05745 to 0.1303
0.02694 -0.009478 to
0.06335
0.06571 0.02929 to 0.1021
-0.06693 -0.1033 to 0.03051
-0.02816 -0.06457 to
0.008258
0.03877 0.002359 to
0.07519

Yes
No

< 0.0001
0.2077

Yes
Yes

0.0002
0.0001

No

0.1765

Yes

0.0334

0.2109
0.1547
0.2077
-0.05628

Yes
Yes
Yes
Yes

< 0.0001
< 0.0001
< 0.0001
0.0011

0.1745 to 0.2474
0.1183 to 0.1911
0.1713 to 0.2441
-0.09270 to 0.01987
-0.003285 -0.03970 to
0.03313
0.053 0.01659 to
0.08941

0.2113
0.1586
0.1954
-0.05269

0.1749 to 0.2477
0.1222 to 0.1950
0.1590 to 0.2318
-0.08910 to 0.01627
-0.01586 -0.05228 to
0.02055
0.03682 0.0004103 to
0.07324

TABLE XV
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No

0.9948

Yes

0.0022

Yes
Yes
Yes
Yes

< 0.0001
< 0.0001
< 0.0001
0.0024

No

0.6434

Yes

0.0467

H358 ALAMAR BLUE STATISTICAL ANALYSIS
H358 Alamar Blue
Within each row, compare columns (simple effects within rows)
Number of families
Number of comparisons per
family
Alpha
Tukey's multiple
comparisons test
Row 1
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

Row 2
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

Row 3
FN vs. IMR90 ECM

4
6
0.05
Mean
Diff.

95% CI of diff.

-1.987E08
-1.987E08
-1.987E08
0

-0.06557 to
0.06557
-0.06557 to
0.06557
-0.06557 to
0.06557
-0.06557 to
0.06557
0 -0.06557 to
0.06557
0 -0.06557 to
0.06557

Significant? Adjusted P
Value

No

> 0.9999

No

> 0.9999

No

> 0.9999

No

> 0.9999

No

> 0.9999

No

> 0.9999

0.08628 0.02071 to
0.1518
0.1088 0.04320 to
0.1743
0.1004 0.03486 to
0.1660
0.0225 -0.04307 to
0.08807
0.01415 -0.05142 to
0.07972
-0.008342 -0.07391 to
0.05723

Yes

0.0061

Yes

0.0005

Yes

0.0013

No

0.7893

No

0.9359

No

0.9857

0.2414 0.1759 to

Yes
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< 0.0001

FN vs. WI38 ECM

0.2667

FN vs. HDF ECM

0.2455

IMR90 ECM vs. WI38 ECM

0.02523

IMR90 ECM vs. HDF ECM

0.004093

WI38 ECM vs. HDF ECM

-0.02114

Row 4
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

0.3070
0.2011 to
0.3322
0.1800 to
0.3111
-0.04034 to
0.09080
-0.06148 to
0.06966
-0.08671 to
0.04443

0.294 0.2284 to
0.3596
0.3383 0.2727 to
0.4038
0.3398 0.2742 to
0.4054
0.04428 -0.02129 to
0.1098
0.0458 -0.01977 to
0.1114
0.001515 -0.06405 to
0.06708

Yes

< 0.0001

Yes

< 0.0001

No

0.726

No

0.9982

No

0.8185

Yes

< 0.0001

Yes

< 0.0001

Yes

< 0.0001

No

0.2785

No

0.2514

No

> 0.9999

TABLE XVI
HPL1D ALAMAR BLUE STATISTICAL ANALYSIS
HPL1D Alamar Blue
Within each row, compare columns (simple effects within rows)
Number of families
Number of comparisons per
family
Alpha
Tukey's multiple

4
6
0.05
Mean

95% CI of diff.
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Significant? Adjusted P

comparisons test
Row 1
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

Row 2
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

Row 3
FN vs. IMR90 ECM
FN vs. WI38 ECM
FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

Row 4
FN vs. IMR90 ECM
FN vs. WI38 ECM

Diff.

Value

-1.987E- -0.05237 to
08 0.05237
0 -0.05237 to
0.05237
2.782E-07 -0.05237 to
0.05237
1.987E-08 -0.05237 to
0.05237
2.98E-07 -0.05237 to
0.05237
2.782E-07 -0.05237 to
0.05237

No

> 0.9999

No

> 0.9999

No

> 0.9999

No

> 0.9999

No

> 0.9999

No

> 0.9999

0.08531 0.03293 to 0.1377
0.1229 0.07049 to 0.1752
0.0195 -0.03287 to
0.07187
0.03755 -0.01482 to
0.08993
-0.06581 -0.1182 to 0.01343
-0.1034 -0.1557 to 0.05099

Yes
Yes
No

0.0006
< 0.0001
0.7455

Yes

< 0.0001

0.3145
0.2348
0.1816
-0.07967

0.2621 to 0.3669
0.1824 to 0.2872
0.1292 to 0.2340
-0.1320 to 0.02730
-0.1329 -0.1853 to 0.08051
-0.05321 -0.1056 to 0.0008385

Yes
Yes
Yes
Yes

< 0.0001
< 0.0001
< 0.0001
0.0014

Yes

< 0.0001

0.3231 0.2708 to 0.3755
0.2765 0.2242 to 0.3289

Yes
Yes
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No

0.231

Yes

0.0093

Yes

0.0453

< 0.0001
< 0.0001

FN vs. HDF ECM
IMR90 ECM vs. WI38 ECM
IMR90 ECM vs. HDF ECM
WI38 ECM vs. HDF ECM

0.2025 0.1501 to 0.2549
-0.04661 -0.09898 to
0.005764
-0.1206 -0.1730 to 0.06827
-0.07403 -0.1264 to 0.02166

Yes
No

< 0.0001
0.0952

Yes

< 0.0001

Yes

TABLE XVII
XENOGRAFT VOLUME STATISTICAL ANALYSIS
Data 1
Xenograft Tumor Volume
Column B
vs.
Column A

A549 +PBS
vs.
A549+ECM

Unpaired t test
P value
P value summary
Significantly different? (P < 0.05)
One- or two-tailed P value?
t, df

0.0718
ns
No
Two-tailed
t=1.884 df=24

How big is the difference?
Mean ± SEM of column A
Mean ± SEM of column B
Difference between means
95% confidence interval
R squared

334.3 ± 48.20, n=13
223.3 ± 33.88, n=13
-111.0 ± 58.92
-232.6 to 10.62
0.1288

F test to compare variances
F,DFn, Dfd
P value
P value summary
Significantly different? (P < 0.05)

2.024, 12, 12
0.2364
ns
No

TABLE XVIII
XENOGRAFT WEIGHT STATISTICAL ANALYSIS
Data 1
Xenograft Weights
58

0.003

Column B
vs.
Column A
Unpaired t test
P value
P value summary
Significantly different? (P <
0.05)
One- or two-tailed P value?
t, df
How big is the difference?
Mean ± SEM of column A
Mean ± SEM of column B
Difference between means
95% confidence interval
R squared
F test to compare variances
F,DFn, Dfd
P value
P value summary
Significantly different? (P <
0.05)

A549+PBS
vs.
A549+ECM

0.0261
*
Yes
Two-tailed
t=2.372 df=24

0.2346 ± 0.03717, n=13
0.1362 ± 0.01849, n=13
-0.09846 ± 0.04151
-0.1841 to -0.01278
0.1899

4.043, 12, 12
0.0223
*
Yes

TABLE XIX
XENOGRAFT WEIGHT STATISTICAL ANALYSIS
Trans-well Migration
Number of families
1
Number of comparisons per
6
family
Alpha
0.05
95% CI of
Significant Summary Adjusted P
diff.
Value
Tukey's multiple
Mean Diff.
comparisons test
A549 FN vs. A549 IMR90
-173.8 to Yes
**
0.0021
88.15
A549 FN vs. A549 WI38
-131 -222.1 to Yes
**
0.0081
59

A549 FN vs. A549 HDF

69.90
-146 -162.9 to 101.6
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Yes

***

0.0008
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